Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial

We present the interim results of the efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac. This was a randomized, observer-blinded, non-inferiority trial (NCT04942405). Volunteers were 18–55 years old and randomized at a 1:1 ratio to receive either TURKOVAC or...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Mine Durusu Tanriover, Ozlem Altuntas Aydin, Rahmet Guner, Orhan Yildiz, Ilhami Celik, Hamdi Levent Doganay, Sukran Kose, Sila Akhan, Emin Halis Akalin, Zafer Sezer, Aykut Ozdarendeli, Serhat Unal, on behalf of the TURKOVAC Study Group
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2022-11-01
Sarja:	Vaccines
Aiheet:	TURKOVAC CoronaVac efficacy safety COVID-19 vaccine
Linkit:	https://www.mdpi.com/2076-393X/10/11/1865
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!